Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for eXoZymes Inc. (EXOZ : NSDQ)

• Company Description    Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA. Number of Employees: 31

• Price / Volume Information    Yesterday's Closing Price: $10.90 Daily Weekly Monthly 20 Day Moving Average: 4,867 shares Shares Outstanding: 8.39 (millions) Market Capitalization: $91.42 (millions) Beta: 2.38 52 Week High: $23.99 52 Week Low: $8.86 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -27.33% -27.21% 12 Week -19.26% -20.56% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 750 Royal Oaks Drive Suite 106 - MONROVIA,CA 91016 USA ph: 626-415-1488 fax: - press@exozymes.com http://www.exozymes.com

• General Corporate Information    Officers Michael Heltzen - Chief Executive Officer and President Christopher A. Marlett - Chairman Fouad Nawaz - Vice President; Finance Anthony DiGiandomenico - Director James U. Bowie - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 461874109 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/30/26 Share - Related Items Shares Outstanding: 8.39 Most Recent Split Date: (:1) Beta: 2.38 Market Capitalization: $91.42 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/30/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 17.01 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 3.57% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -104.58 06/30/25 - -134.50 ROA 12/31/25 - - 09/30/25 - -79.55 06/30/25 - -81.63 Current Ratio 12/31/25 - - 09/30/25 - 4.53 06/30/25 - 6.19 Quick Ratio 12/31/25 - - 09/30/25 - 4.53 06/30/25 - 6.19 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 0.64 06/30/25 - 0.86 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.01 06/30/25 - 0.01 Debt-to-Capital 12/31/25 - - 09/30/25 - 1.41 06/30/25 - 1.19

Powered by Zacks Investment Research ©